Pfizer gets preliminary injunction halting sale of generic Accupril
Pfizer Inc., the world''s largest research-based pharmaceuticals firm, said a court has ordered two competitors to stop selling a generic version of its blood-pressure medication Accupril, the Associated Press reports. Pfizer said it obtained a preliminary injunction barring Teva Pharmaceuticals Inc. and Ranbaxy Pharmaceuticals Inc. from marketing generic quinapril, which the companies launched in December. The U.S. District Court of New Jersey indicated that Pfizer was likely to win its patent infringement suit against Teva and Ranbaxy, and ordered the temporary ban while the company seeks a permanent injunction, Pfizer said. Following the ruling, Pfizer said it also intends to seek damages from lost sales.